Unfractionated Heparin for Hemodialysis: Still the Best Option

Seminars in Dialysis

Volumn 23, Issue 5, 2010, Pages 510-515

  Cronin, Robert E ^a   Reilly, Robert F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BIOMATERIAL; HEPARIN;

ARTICLE; CHRONIC KIDNEY FAILURE; HUMAN; INSTRUMENTATION; RENAL REPLACEMENT THERAPY;

ANTICOAGULANTS; COATED MATERIALS, BIOCOMPATIBLE; HEPARIN; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 78049421004     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2010.00770.x     Document Type: Article

References (49)

1. Ouseph R, Brier ME, Ward RA: Improved dialyzer reuse after use of a population pharmacodynamic model to determine heparin doses. Am J Kidney Dis 35(1):89-94, 2000
2. Brunet P, Simon N, Opris A, Faure V, Lorec-Penet AM, Portugal H, Dussol B, Berland Y: Pharmacodynamics of unfractionated heparin during and after a hemodialysis session. Am J Kidney Dis 51(5):789-795, 2008
3. Guillet B, Simon N, Sampol JJ, Lorec-Penet AM, Portugal H, Berland Y, Dussol B, Brunet P: Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant 18(11):2348-2353, 2003
4. Davenport A: Review article: low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatments. Nephrology (Carlton) 14(5):455-461, 2009
5. Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten H, Ronco C, Kellum JA: Continuous renal replacement therapy: a worldwide practice survey The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med 33(9):1563-1570, 2007
6. Caruana RJ, Raja RM, Bush JV, Kramer MS, Goldstein SJ: Heparin free dialysis: comparative data and results in high risk patients. Kidney Int 31(6):1351-1355, 1987
7. Sanders PW, Taylor H, Curtis JJ: Hemodialysis without anticoagulation. Am J Kidney Dis 5(1):32-35, 1985
8. Stamatiadis DN, Helioti H, Mansour M, Pappas M, Bokos JG, Stathakis CP: Hemodialysis for patients bleeding or at risk for bleeding, can be simple, safe and efficient. Clin Nephrol 62(1):29-34, 2004
9. Sagedal S, Hartmann A, Osnes K, Bjørnsen S, Torremocha J, Fauchald P, Kofstad J, Brosstad F: Intermittent saline flushes during haemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of dalteparin. Nephrol Dial Transplant 21(2):444-449, 2006
10. Kossmann RJ, Gonzales A, Callan R, Ahmad S: Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study. Clin J Am Soc Nephrol 4(9):1459-1464, 2009
11. Frank RD, Muller U, Lanzmich R, Groeger C, Floege J: Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits. Nephrol Dial Transplant 21(4):1013-1018, 2006
12. Lavaud S, Canivet E, Wuillai A, Maheut H, Randoux C, Bonnet JM, Renaux JL, Chanard J: Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane. Nephrol Dial Transplant 18(10):2097-2104, 2003
13. Chanard J, Lavaud S, Maheut H, Kazes I, Vitry F, Rieu P: The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane. Nephrol Dial Transplant 23(6):2003-2009, 2008
14. Evenepoel P, Dejagere T, Verhamme P, Claes K, Kuypers D, Bammens B, Vanrenterghem Y: Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding. Am J Kidney Dis 49(5):642-649, 2007
15. Murray PT, Reddy BV, Grossman EJ, Hammes MS, Trevino S, Ferrell J, Tang I, Hursting MJ, Shamp TR, Swan SK: A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 66(6):2446-2453, 2004
16. Hursting MJ, Murray PT: Argatroban anticoagulation in renal dysfunction: a literature analysis. Nephron Clin Pract 109(2):c80-c94, 2008
17. Apsner R, Buchmayer H, Gruber D, Sunder-Plassmann G: Citrate for long-term hemodialysis: prospective study of 1, 009 consecutive high-flux treatments in 59 patients. Am J Kidney Dis 45(3):557-564, 2005
18. Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R, Coates G, Webber C: Heparin effect on bone density. Thromb Haemost 64(2):286-289, 1990
19. Wise PH, Hall AJ: Heparin-induced osteopenia in pregnancy. Br Med J 281(6233):110-111, 1980
20. Le Templier G, Rodger MA: Heparin-induced osteoporosis and pregnancy. Curr Opin Pulm Med 14(5):403-407, 2008
21. Rodger MA, Kahn SR, Cranney A, Hodsman A, Kovacs MJ, Clement AM, Lazo-Langner A, Hague WM; TIPPS Investigators: Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. J Thromb Haemost 5(8):1600-1606, 2007
22. Kwan BC, Kronenberg F, Beddhu S, Cheung AK: Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 18(4):1246-1261, 2007
23. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360(14):1395-1407, 2009
24. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353(3):238-248, 2005
25. Bagdade JD, Porte D Jr, Bierman EL: Hypertriglyceridemia. A metabolic consequence of chronic renal failure. N Engl J Med 279(4):181-185, 1968
26. Bagdade JD, Yee E, Wilson DE, Shafrir E: Hyperlipidemia in renal failure: studies of plasma lipoproteins, hepatic triglyceride production, and tissue lipoprotein lipase in a chronically uremic rat moedl. J Lab Clin Med 91(1):176-186, 1978
27. Cheung AK: Is lipid control necessary in hemodialysis patients? Clin J Am Soc Nephrol 4(Suppl 1):S95-S101, 2009
28. Savdie E, Gibson JC, Crawford GA, Simons LA, Mahony JF: Impaired plasma triglyceride clearance as a feature of both uremic and posttransplant triglyceridemia. Kidney Int 18(6):774-782, 1980
29. Nasstrom B, Stegmayr B, Gupta J, Olivecrona G, Olivecrona T: A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing. Nephrol Dial Transplant 20(6):1172-1179, 2005
30. Elisaf MS, Germanos NP, Bairaktari HT, Pappas MB, Koulouridis EI, Siamopoulos KC: Effects of conventional vs. low-molecular-weight heparin on lipid profile in hemodialysis patients. Am J Nephrol 17(2):153-157, 1997
31. Kronenberg F, Konig P, Lhotta K, Steinmetz A, Dieplinger H: Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients. Clin Nephrol 43(6):399-404, 1995
32. Saltissi D, Morgan C, Westhuyzen J, Healy H: Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrol Dial Transplant 14(11):2698-2703, 1999
33. Oster JR, Singer I, Fishman LM: Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 98(6):575-586, 1995
34. Hottelart C, Achard JM, Moriniere P, Zoghbi F, Dieval J, Fournier A: Heparin-induced hyperkalemia in chronic hemodialysis patients: comparison of low molecular weight and unfractionated heparin. Artif Organs 22(7):614-617, 1998
35. Gheno G, Cinetto L, Savarino C, Vellar S, Carraro M, Randon M: Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin. Eur J Clin Pharmacol 59(5-6):373-377, 2003
36. Lemke HD, Kuentz F, Foret M: Mechanisms of hypersensitivity reactions during hemodialysis. Trans Am Soc Artif Intern Organs 31:149-154, 1985
37. Berkun Y, Haviv YS, Schwartz LB, Shalit M: Heparin-induced recurrent anaphylaxis. Clin Exp Allergy 34(12):1916-1918, 2004
38. Scherer K, Tsakiris DA, Bircher AJ: Hypersensitivity reactions to anticoagulant drugs. Curr Pharm Des 14(27):2863-2873, 2008
39. Jappe U: Allergy to heparins and anticoagulants with a similar pharmacological profile: an update. Blood Coagul Fibrinolysis 17(8):605-613, 2006
40. Syed S, Reilly RF: Heparin-induced thrombocytopenia: a renal perspective. Nat Rev Nephrol 5(9):501-511, 2009
41. Hutchison CA, Dasgupta I: National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant 22(6):1680-1684, 2007
42. Warkentin TE, Kelton JG: A 14-year study of heparin-induced thrombocytopenia. Am J Med 101(5):502-507, 1996
43. Golper TA, Ward RA: Dialysate. Ho-hum! Clin J Am Soc Nephrol 4(9):1403-1404, 2009
44. Matsuo T, Kusano H, Wanaka K, Ishihara M, Oyama A: Heparin-induced thrombocytopenia in a uremic patient requiring hemodialysis: an alternative treatment and reexposure to heparin. Clin Appl Thromb Hemost 13(2):182-187, 2007
45. Warkentin TE, Sheppard JA: Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev 20(4):259-272, 2006
46. Bryant A, Low J, Austin S, Joseph JE: Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T's score and particle gel immunoassay. Br J Haematol 143(5):721-726, 2008
47. Warkentin TE: Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121(4):535-555, 2003
48. Crowther MA, Cook DJ, Albert M, Williamson D, Meade M, Granton J, Skrobik Y, Langevin S, Mehta S, Hebert P, Guyatt GH, Geerts W, Rabbat C, Douketis J, Zytaruk N, Sheppard J, Greinacher A, Warkentin TE; Canadian Critical Care Trials Group: The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care 25:287-293, 2010
49. Carrier M, Rodger MA, Fergusson D, Doucette S, Kovacs MJ, Moore J, Kelton JG, Knoll GA: Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex. Kidney Int 73(2):213-219, 2008